1. Home
  2. STKE vs SCYX Comparison

STKE vs SCYX Comparison

Compare STKE & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

STKE

Sol Strategies Inc.

HOLD

Current Price

$1.06

Market Cap

38.3M

Sector

N/A

ML Signal

HOLD

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

HOLD

Current Price

$3.76

Market Cap

42.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STKE
SCYX
Founded
2002
1999
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
38.3M
42.4M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
STKE
SCYX
Price
$1.06
$3.76
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$3.00
AVG Volume (30 Days)
417.7K
78.7K
Earning Date
05-15-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
61.36
EPS
N/A
N/A
Revenue
N/A
$257,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$552.94
$608.78
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.85
$0.57
52 Week High
$7.75
$5.62

Technical Indicators

Market Signals
Indicator
STKE
SCYX
Relative Strength Index (RSI) 39.14 43.82
Support Level $0.90 $3.68
Resistance Level $1.42 $5.10
Average True Range (ATR) 0.11 0.37
MACD -0.02 -0.16
Stochastic Oscillator 5.64 3.18

Price Performance

Historical Comparison
STKE
SCYX

About STKE Sol Strategies Inc.

Sol Strategies Inc is engaged in investing in blockchain technologies and crypto currencies. Company executes its Investment Objective through three lines of effort: Treasury management: Maintaining a core portfolio of cryptocurrencies for long-term growth, enhanced with risk management strategies to minimize volatility, and generating yield through lending, staking, and liquidity provisioning; Private equity focused on early stage companies in the DeFi and blockchain sectors; and Active investments to generate yield through strategic activities, including Bitcoin mining and stalking and validating Solana.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: